microbiome News
-
Medbiome`s founders demonstrated that structurally similar compounds can have distinct effects on individual microbiomes
In a recent paper in Gut Microbes the founders of MedBiome reported the effects of berberine (BBR) and 16 structural analogs on seven individual gut microbiomes using our RapidAIM technology. This article clearly illustrates that the RapidAIM technology can distinguish the effects of structurally similar compounds on individual microbiomes. This is an important milestone when selecting and ...
-
MetaboGen at the Microbiome Drug Development Summit, Paris Jan 24-25
On January 24-26, MetaboGen will attend the 1st Microbiome Drug Development Summit Europe, taking place in Paris. Meet us there! Read more: ...
By Metabogen AB
-
Testing of a Drug Panel for effects on the gut Microbiome using RapidAIM
MedBiome’s founders reported in Microbiome the development of the RapidAIM platform to screen compounds against individual microbiomes in vitro. They tested 43 compounds (including 4 antibiotics) against 5 individual microbiomes using the RapidAIM technology. The RapidAIM workflow provides insights into microbiome absolute abundance and functional responses to drugs. ...
-
EnteroBiotix CEO featured on The Pharma Letter podcast talking about mastering the microbiome
Our Founder & CEO Dr James McIlroy was recently featured on The Pharma Letter podcast with Simon Wentworth discussing mastering the microbiome. James discusses how EnteroBiotix is developing its pipeline of highly diverse microbiome enhancing therapeutics through a unique approach to development and manufacturing, focussed on supply chain control and novel technologies. Listen here to ...
-
Bio-Me at 4th National Microbiota Conference
During the 4th Norwegian National Microbiota Conference to be held in Oslo, Norway on 9th November, Dr. Morten Isaksen, CEO of Bio-Me has been invited to present Bio-Me and its contribution to use of information from the gut microbiome in clinical settings. The Conference gathers different groups that work within the field of microbiome/microbiota related aspects in Norway. This field is ...
By Bio-Me
-
Symberix CEO Presents at Translational Microbiome Conference
Dr. Ward Peterson delivered a presentation entitled “When Good Bugs Do Bad Things: Targeting the Microbiome to Make Better Human Genome-Targeted Drugs” at the annual Translational Microbiome Conference on May 14, 2015 in Boston. The Conference focused on the potential for translational interventions in microbiome research and the challenges the industry will need to address to make ...
-
Joint webinar of Thermo Fisher Scientific and Bio-Me on September 22nd with focus on how the PMP technology can support researchers and industry
On September 22nd Warren Flood, Ph.D. and COO of Bio-Me, will participate in a webinar organized together with Thermo Fisher Scientific with the title “Missing a piece of the puzzle? Factor in the gut microbiome”. There, he will present how our PMP platform, based on Thermo Fisher Scientific’s OpenArray qPCR technology, helps researchers and industry translating their gut ...
By Bio-Me
-
Symberix Co-Founder Gives Keynote Address at AACR Conference
Symberix co-founder Matthew Redinbo gave the keynote address at the AACR Microbiome, Viruses, and Cancer conference on Friday, February 21, 2020. The special conference covers the contribution of bacterial, viral, and fungal pathogens to the development of cancers, as well as the impact of the microbiome on cancer therapy. Dr. Redinbo’s keynote, titled “Molecular control of the gut ...
-
Microviable Therapeutics is hiring!
As part of our growth and consolidation as a microbiome company focused on therapeutics we have several openings to join our team! Are you ready to rock? Check out our careers section and submit your credentials: Microviable careers ...
-
MetaboGen reaches development goal - first product ready for safety study
BioGaia today announced that its´ subsidiary MetaboGen has reached an important development goal. The first version of its next generation probiotic product is now ready for a safety study. MetaboGen focuses its research on the microbiome and on finding breakthrough opportunities that can be developed into novel therapeutics and the next generation of probiotics. A number of development ...
By Metabogen AB
-
Dr. Warren Flood steps up as CEO of Bio-Me
Microbiome precision medicine company Bio-Me today announced that Dr. Warren Flood has become CEO following his successful period as COO. Previous CEO Dr. Morten Isaksen moves up to the Board and will also continue as Chief Innovation Officer with a focus on longer term and higher-value clinical applications for the company’s Precision Microbiome Profiling (PMP™) technology. These ...
By Bio-Me
-
Be First to See the Future Food-Tech San Francisco Program
We’re excited to announce the program for the upcoming Future Food-Tech San Francisco summit in San Francisco as part of Rethink Ag & Food Innovation Week, 2017. Featuring our pick of the industry’s most innovative brands, entrepreneurs and investors, we’ve created an interactive agenda that’s set to spark dynamic debate. From Virtual Reality to Alternative Proteins ...
-
Intus Bio Announces New Distribution Partnership with BioCat GmbH to Accelerate Microbiome Research in Germany, Austria and Switzerland
Intus Bios, a microbiome research company that develops complete solutions for characterizing microbiome populations down to the strain level, has entered into an exclusive distribution partnership with BioCat GmbH, a leading provider of life sciences solutions, for the promotion, sale and support of all Intus Biosciences products and software in Germany, Austria, and Switzerland. Founded in ...
-
Intus Bio’s management system certified to ISO 9001
Intus Bio, a microbiome research company that develops tools for characterizing microbiome populations down to the strain level, has been awarded ISO 9001:2015 certification. The company received the certificate for its management system on Nov. 4, 2020. It recognizes Intus Bio’s commitment to quality through an effective quality management system. ISO 9001:2015 is a standard issued by ...
-
Our co-founders and SAB scientific publications among the Top 100 in Cell and Molecular Biology
Last week, the Nature Group Scientific Reports journal published the top 100 most downloaded cell and molecular biology papers. This comprehensive list featured an outstanding publication from our co-founders and SAB members on Precision modification of the human gut microbiota based on selective targeting of surface-associated proteins.Importantly, it is one of the few manuscripts ...
-
Intus Bio’s Partners with Inqaba Biotechnical Industries to Accelerate Microbiome Research in Sub-Saharan Africa
Intus Bio, a microbiome research company that develops complete solutions for characterizing microbiome populations down to the strain level, has entered into a partnership with Inqaba Biotechnical Industries (Pty) Ltd for product distribution and StrainID™ services in Sub-Saharan Africa. Inqaba Biotechnical Industries (Pty) Ltd, trading as inqaba biotec™, is a unique South African ...
-
Microviable will be attending Pharmabiotics Event 2022
Our CEO Claudio Hidalgo will be attending the Pharmabiotics Event 2022 taking place on April 20th-21st at Lyon. The Pharmabiotics Conference brings together players from academia and industry and it is an incredible opportunity to meet stakeholders and discuss the further innovation in microbiome-based drug products and regulatory affairs. Reach out to us if you want to meet during the ...
-
Microviable Therapeutics to enter into a contractual agreement with BCD Bioscience
Microviable Therapeutics SL (Gijón, Asturias, Spain), announced a contractual agreement with BCD Bioscience Inc. (California, USA) to work on microbial fermentation and novel prebiotics to modulate the human gut microbiome. Microviable expertise on gut microbiome research will enable to conveniently process microbiota samples for fermentation applications that coupled with BCD ...
-
Synbiotic Health Appoints Erin Vyhlidal as VP Corporate Finance
Microbiome-based ingredient company Synbiotic Health is pleased to announce the appointment of Erin Vyhlidal as Controller and Vice President, Corporate Finance. Vyhlidal is a CPA (inactive registrant) with twenty years’ experience in accounting. She previously oversaw a team of nine as VP Corporate Finance at Farmers National Company in Omaha, NE, after working at PricewaterhouseCoopers as ...
-
EnteroBiotix completes new manufacturing facility focused on gut microbiome therapies
EnteroBiotix, a Scottish biopharma focused on making gut microbiome therapies, said construction of its new manufacturing, lab and office facility has been completed. Located at the Strathclyde Business Park in Bellshill, the 20,000-square-foot facility is designed to meet regulatory biologics requirements and product analysis while providing the company end-to-end control of its supply chain, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you